Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019; 18: 43-48
Результаты мультицентрового исследования лечения пациентов детского возраста с впервые установленной первичной медиастинальной в-клеточной лимфомой по протоколам В-НХЛ-М-10 и Da-EPOCH-R
https://doi.org/10.24287/1726-1708-2019-18-1-43-48Аннотация
В последние годы международным стандартом лечения первичной медиастинальной В-клеточ-ной лимфомы (ПМВКЛ) стало использование химиотерапии в режиме Dа-EPOCH-R. Цель работы: оценить результаты мультицентрового международного исследования у пациентов детского возраста по протоколам B-НХЛ-М-Ю и Da-EPOCH-R. Настоящее исследование поддержано Независимым этическим комитетом и утверждено решением Ученого совета НМИЦ ДГОИ им. Дмитрия Рогачева. В исследовании участвуют более 20 клиник Российской Федерации и Республики Беларусь (Минск). С января 2011 по июль 2017 года зарегистрированы 246 пациентов с впервые установленным диагнозом «неходжкинская лимфома» (НХЛ), из них с ПМВКЛ - 18 (7,3%) детей. Среди 18 больных с ПМВКЛ 10 (55,5%) получали терапию по протоколу B-NHL-10; по протоколу Da-EPOCH-R - 8 (44,4%). Медиана наблюдения составила 3 года. Бессобытийная выживаемость по протоколу В-НХЛ-М-10 - 70%, по протоколу - Da-EPOCH-R - 67%.
Список литературы
1. Румянцев А.Г., Масчан А.А. Федеральные клинические рекомендации по диагностике и лечению неходжкинских лимфом. - М., 2014.
2. Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version. 2018 Dec 18. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002. Available from: https://www.ncbi.nlm.nih.gov/books/NBK65738/
3. Oschlies I. Burkhardt B., Salave-rria I., Rosenwald A., d'Amore E.S., Szcze-panowski M., et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children». Haematologica 2011; 96 (2): 262-8.
4. Martelli M., Ferreri A., Di Rocco A., Ansuinelli M., Johnson P.W.M. Pri-mary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol 2017 May; 113: 318-27. Doi: 10.1016/j.critrevonc.2017.01.009. Epub 2017 Jan 21.
5. Dunleavy K. Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2017 Dec 8; 2017 (1): 298-303. Doi: 10.1182/asheducation-2017.1.298
6. Rauthe S., Rosenwald A. Mediastinal lymphomas. Pathologe 2016 Sep; 37 (5): 457-64. Doi: 10.1007/s00292-016-0199-z
7. Zinzani P.L., Ribrag V., Moskowitz C.H., Michot J.M., Kuruvilla J., Balakuma-ran A., et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinallarge B-cell lymphoma. Blood 2017 Jul 20; 130 (3): 267-70. Doi: 10.1182/blood-2016-12-758383. Epub 2017 May 10.
8. Самочатова Е.В., Шелихова Л.Н. Лечение неходжкинских лимфом и острого лейкоза из зрелых В-клеток у детей и подростков по данным региональных российских клиник. Онкогематология 2011; 1: 30-5.
9. Giulino-Roth L., O'Donohue T., Chen Z., Bartlett N.L., LaCasce A., Martin Doyle W. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol 2017 Dec; 179 (5): 739-47. Doi: 10.1111/bjh.14951. Epub 2017 Oct 29
10. Melani C., Roschewski M., Wilson W.H. End-Of-Treatment And Serial PET Imaging Has Prognostic Value And Clinical Utility In Primary Mediastinal B-Cell Lymphoma Following Dose-Adjusted EPOCH-R -Response» Haematologica 2018 Aug; 103: e382. Doi :10.3324/haematol.2018.199547
11. Adams H.J., Kwee T.C. Unproven value of end-of-treatment and serial followup FDG-PET in primary mediastinal B-cell lymphoma. Haematologica 2018; 103 (8): e380-1. Doi: 10.3324/haematol.2018.198523
12. Petkovic I. Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn) 2015; 19 (6): 428-35. Published online 2015 Dec 16. Doi: 10.5114/wo.2015.56388. PMCID: PMC4731448
13. Dunleavy K., Pittaluga S., Maeda L.S., Advani R., Chen C.C., Hessler J., et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013 Apr 11; 368 (15): 1408-16.
Pediatric Hematology/Oncology and Immunopathology. 2019; 18: 43-48
Results of multicenter international trail for pediatric primary mediastinal B-cell lymphoma treated according to protocols B-NHL-M-10 and DA-EPOCH-R
https://doi.org/10.24287/1726-1708-2019-18-1-43-48Abstract
During last years dose-adjusted EPOCH chemotherapy has become the most common international fist-line regimen of treatment of primary mediastinal B-cell lymphoma ^МВ^). Our goal is to evaluate results of multicentre international trail of treatment for children with PMBCL according to B-NHL-М-Ю and with dose-adjusted EPOCH protocol. This study was supported by the Independent Ethical Committee of State Nature Research Institute and approved by the decision of the Academic Council. More than 20 clinics from Russian Federetion and republic of Belarus are involved in this reaserch. Since January 2011 to June 2017 246 patients with first diagnosed NHL were included in the study, 18 of them had PMBCL (7.3%). Results: 10 patients (55.5%) were treated according to BNHL protocol, 8 (44.4%) patients received Dа-EPOCH-R protocol. With median follow-up of 3-year, EFS for patients with treatment according to B-NHL-М-Ю protocol was 70% for other with Dа-EPOCH-R - 67%.
References
1. Rumyantsev A.G., Maschan A.A. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniyu nekhodzhkinskikh limfom. - M., 2014.
2. Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version. 2018 Dec 18. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002. Available from: https://www.ncbi.nlm.nih.gov/books/NBK65738/
3. Oschlies I. Burkhardt B., Salave-rria I., Rosenwald A., d'Amore E.S., Szcze-panowski M., et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children». Haematologica 2011; 96 (2): 262-8.
4. Martelli M., Ferreri A., Di Rocco A., Ansuinelli M., Johnson P.W.M. Pri-mary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol 2017 May; 113: 318-27. Doi: 10.1016/j.critrevonc.2017.01.009. Epub 2017 Jan 21.
5. Dunleavy K. Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2017 Dec 8; 2017 (1): 298-303. Doi: 10.1182/asheducation-2017.1.298
6. Rauthe S., Rosenwald A. Mediastinal lymphomas. Pathologe 2016 Sep; 37 (5): 457-64. Doi: 10.1007/s00292-016-0199-z
7. Zinzani P.L., Ribrag V., Moskowitz C.H., Michot J.M., Kuruvilla J., Balakuma-ran A., et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinallarge B-cell lymphoma. Blood 2017 Jul 20; 130 (3): 267-70. Doi: 10.1182/blood-2016-12-758383. Epub 2017 May 10.
8. Samochatova E.V., Shelikhova L.N. Lechenie nekhodzhkinskikh limfom i ostrogo leikoza iz zrelykh V-kletok u detei i podrostkov po dannym regional'nykh rossiiskikh klinik. Onkogematologiya 2011; 1: 30-5.
9. Giulino-Roth L., O'Donohue T., Chen Z., Bartlett N.L., LaCasce A., Martin Doyle W. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol 2017 Dec; 179 (5): 739-47. Doi: 10.1111/bjh.14951. Epub 2017 Oct 29
10. Melani C., Roschewski M., Wilson W.H. End-Of-Treatment And Serial PET Imaging Has Prognostic Value And Clinical Utility In Primary Mediastinal B-Cell Lymphoma Following Dose-Adjusted EPOCH-R -Response» Haematologica 2018 Aug; 103: e382. Doi :10.3324/haematol.2018.199547
11. Adams H.J., Kwee T.C. Unproven value of end-of-treatment and serial followup FDG-PET in primary mediastinal B-cell lymphoma. Haematologica 2018; 103 (8): e380-1. Doi: 10.3324/haematol.2018.198523
12. Petkovic I. Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn) 2015; 19 (6): 428-35. Published online 2015 Dec 16. Doi: 10.5114/wo.2015.56388. PMCID: PMC4731448
13. Dunleavy K., Pittaluga S., Maeda L.S., Advani R., Chen C.C., Hessler J., et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013 Apr 11; 368 (15): 1408-16.
